The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -17,119,438 |
| Depreciation and amortization | 17,280 |
| Accretion of discounts on available for sale debt securities, net | 196,427 |
| Non-cash lease adjustments | 189,897 |
| Issuance of restricted common stock for services | 366,900 |
| Stock-based compensation | 650,877 |
| Foreign currency remeasurement (gain) loss | 157,965 |
| Realized gain on redemptions of available for sale debt securities | 22,408 |
| Realized loss on equity securities | 264,913 |
| Unrealized gain on equity securities | 305,887 |
| Operating lease liabilities | -190,625 |
| Prepaid expenses & other current assets | -554,095 |
| Accounts payable and accrued expenses | 271,808 |
| Net cash flows used in operating activities | -15,676,980 |
| Purchase of property and equipment | 1,715 |
| Purchase of marketable securities | 14,721,983 |
| Redemptions of marketable securities | 25,780,771 |
| Net cash flows provided by investing activities | 11,057,073 |
| Proceeds from option exercises | 13,442 |
| Proceeds from the issuance of common stock under the atm sales agreement | 1,624,547 |
| Payments of offering cost related to the atm sales agreement | 139,749 |
| Net cash flows provided by financing activities | 1,498,240 |
| Effect of foreign exchange rates on cash | 33,426 |
| Change in cash and cash equivalents for the year | -3,088,241 |
| Cash and cash equivalents, beginning of year | 7,511,079 |
| Cash and cash equivalents, end of year | 4,422,838 |
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)